Free Trial!
Today’s Best Stocks To Trade! Click Here
Favrille Inc. (NASDAQ: FVRL | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system. Its principal product candidate includes Specifid, a following rituxan induction therapy that is in phase III trial for the treatment of B-cell non-hodgkin's lymphoma (NHL); a following rituxan induction therapy, which is in phase II trial for treating -naive or relapsed or refractory follicular B-cell NHL patients; a single therapeutic agent in relapsed or refractory NHL patients that is in phase II clinical trial; a following autologous stem cell transplantation therapy, which is in phase II clinical trial; a physician-sponsored phase II clinical trial product with maintenance rituxan for the treatment of indolent B-cell NHL; a phase II clinical trial product for patients with various forms of indolent B-cell NHL; and a phase II clinical trial product for patients, who have received prior therapy for their follicular B-cell NHL. The company's other products include FAV-201, a t-cell receptor-based immunotherapy for previously treated patients that is in investigational new drug stage; and anti-CD20 antibodies, which are in preclinical development stage. Favrille was founded in 2000 and is based in San Diego, California. With 41.17 million shares outstanding and 982,200 shares declared short as of May 2008, there is no longer a failure to deliver in shares of FVRL. According to quarterly data provided by the SEC, there were still 12,348 shares of FVRL that were failing-to-deliver as of August 29, 2007.
GenVec Inc. (NASDAQ: GNVC | Quote | Chart | News | PowerRating) a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines. The company's gene-based therapeutic product candidates use its proprietary adenovector technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease. Its lead product candidate, TNFerade Biologic, is an adenovector, which contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with anti-cancer effects. GenVec is developing TNFerade Biologic, which is in phase II/III pivotal trial for the treatment of advanced pancreatic cancer; in Phase I/II clinical trials for the treatment of head and neck cancer; and in Phase II clinical trials for the treatment of in rectal cancer and metastatic melanoma. It also develops AdPEDF, a dose-escalation Phase I clinical trial completed product for the treatment of wet age-related macular degeneration; and TherAtoh that restores hearing or balance function through the regeneration of critical cells of the inner ear. In addition, the company's vaccine programs utilize the adenovector technology platform and its proprietary 293-ORF6 cell line to develop vaccine candidates for infectious diseases, such as malaria, HIV, respiratory syncytial virus, HSV-2, and influenza, as well as vaccine and anti-viral product candidates for the prevention and containment of foot and mouth disease. It has collaboration agreements with the United States Department of Agriculture; the United States Naval Medical Research Center; PATH's Malaria Vaccine Initiative; the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and Fuso Pharmaceuticals Industries, Ltd. The company was founded in 1992 and is based in Gaithersburg, Maryland. With 77.12 million shares outstanding and 5.57 million shares declared short as of May 2008, there is no longer a failure to deliver in shares of GNVC. According to quarterly data provided by the SEC, there were still 41,531 shares of GNVC that were failing-to-deliver as of September 27, 2007.
HydroGen Corp. (NASDAQ: HYDG | Quote | Chart | News | PowerRating) a development stage company, through its wholly-owned subsidiary, HydroGen, LLC, engages in the design, manufacture, marketing, and distribution of fuel cell modules and energy systems using phosphoric acid fuel cells in the United States. The company manufactures multi-megawatt fuel cell systems utilizing proprietary 400-kilowatt phosphoric acid fuel cell technology. Its products are intended to serve industrial and utility markets for distributed power generation. HydroGen Corporation was founded in 2001 and is headquartered in Cleveland, Ohio. With 12.77 million shares outstanding and 151,600 shares declared short as of May 2008, there is no longer a failure to deliver in shares of HYDG. According to quarterly data provided by the SEC, there were still 59,145 shares of HYDG that were failing-to-deliver as of September 20, 2007.
Orion Energy Systems Inc. (NASDAQ: OESX | Quote | Chart | News | PowerRating) designs, manufactures, and implements energy management systems, which consists primarily of energy efficient lighting systems, controls, and related services. The company offers Compact Modular, a HIF lighting system, which operates at lower temperatures than high intensity discharge fixtures and other legacy lighting fixtures in commercial and industrial facilities. Its Compact Modular product line also includes modular power pack, which enables to customize the customers' lighting systems to achieve their specified lighting and energy savings goals. The company's products also include intelite motion control and ambient light sensors, which turn individual fixtures on and off based on user-defined parameters regarding motion and/or light levels in a given area; Apollo Light Pipe, a lens-based device that collects and focuses daylight; and wireless control devices, which allows to remotely communicate with and give commands to individual light fixtures through Web-based software. In addition, it offers various other HIF fixtures to address the lighting and energy management needs, including fixtures for agribusinesses and private label resale. Further, the company provides energy management services, including comprehensive site assessment, site field verification, utility incentive and government subsidy management, engineering design, project management, installation services, and recycling in connection with its retrofit installations. It primarily sells its products directly to commercial and industrial customers; and indirectly through their electrical contractors or distributors. Orion Energy Systems, Inc. was founded in 1996 and is headquartered in Manitowoc, Wisconsin. With 26.94 million shares outstanding and 3.05 million shares declared short as of May 2008, there is no longer a failure to deliver in shares of OESX.
Oscient Pharmaceuticals Corp. (NASDAQ: OSCI | Quote | Chart | News | PowerRating) a commercial-stage biopharmaceutical company, sells and markets products to community-based primary care physicians through its primary care sales force in the United States. The company markets ANTARA (fenofibrate) capsules, a cardiovascular product used for the treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet; and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic used for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. It also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of clostridium difficile-associated disease. Oscient Pharmaceuticals was founded in 1961 as Genome Therapeutics and changed its name in 2004. The company is headquartered in Waltham, Massachusetts. With 14.13 million shares outstanding and 859,200 shares declared short as of May 2008, there is no longer a failure to deliver in shares of OSCI. According to quarterly data provided by the SEC, there were still 36,290 shares of OSCI that were failing-to-deliver as of September 27, 2007.
Palm Harbor Homes Inc. (NASDAQ: PHHM | Quote | Chart | News | PowerRating) together with its subsidiaries, engages in the manufacture and marketing of factory-built homes in the United States. The company manufactures a range of single and multi-section manufactured and modular homes, including ranch-style homes. It also builds single-section homes, split-level homes, cape cod style homes, two and three story homes, and multi-family units, such as apartments and duplexes. In addition, the company offers conforming mortgages to purchasers of factory-built homes sold by company-owned retail sales centers, and independent retail dealers, builders, and developers. Further, it provides property and casualty insurance, as well as extended warranties for owners of manufactured homes. The company sells its products through a distribution network, consisting of its retail sales centers, independent dealers, builders, and developers. As of March 28, 2008, it sold homes through 87 company-owned retail sales centers and builder locations, and approximately 275 independent retail dealers, builders, and developers. The company was founded in 1977 and is headquartered in Addison, Texas. With 22.85 million shares outstanding and 3.58 million shares declared short as of May 2008, there is no longer a failure to deliver in shares of PHHM. According to quarterly data provided by the SEC, there were still 29,860 shares of PHHM that were failing-to-deliver as of September 28, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,000,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
